No Data
No Data
Many Still Looking Away From Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096)
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) price-to-earnings (or "P/E") ratio of 21.9x might make it look like a buy right now compared to the market in China, where around half of th
Baicheng Medicine (301096.SZ): plans to transfer 70% ownership of Category 2 improved new drug 2022HY052 for 70 million yuan.
On June 27th, Gelonhui reported that Baicheng Medicine (301096.SZ) announced that due to the company's operational needs, the company recently reached a cooperation intention with Beijing Yuanfang Tongda Medical Technology Co., Ltd. on the joint investment and development of a Class 2 improved new drug 2022HY052 (hereinafter referred to as "this product") and signed a "Technology Development (Cooperation) Contract". The company will transfer 70% of the property rights of this product for 70 million yuan to Beijing Yuanfang Tongda Medical Technology Co., Ltd., and continue to be responsible for all related work such as research and development, clinical trials and production of this product.
Baicheng Pharmaceutical (301096.SZ) 2023 annual equity distribution: 3 yuan for every 10 shares, share registration on May 31
Baicheng Pharmaceutical (301096.SZ) issued an announcement. The company's 2023 equity distribution plan is: With the company's current...
Pacific Securities: The pharmaceutical industry is under short-term pressure, and future policies will be frequent or enhance the certainty of clinical CRO benefits
With the end of the Fed's interest rate hike cycle, gradual easing of liquidity is expected to bring about a recovery in investment and financing, and overseas demand will improve ahead of local demand; future innovative drug support policies may be introduced intensively, and clinical CRO benefits are highly certain.
BIOS2207 drug independently developed by Baicheng Pharmaceutical (301096.SZ) obtained approval for clinical trials
Baicheng Pharmaceutical (301096.SZ) issued an announcement. Zhejiang Symer Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received...
Baicheng Pharmaceutical (301096.SZ) announced its 2023 annual results, with net profit of 272 million yuan, an increase of 40.07% over the previous year
Baicheng Pharmaceutical (301096.SZ) released its 2023 annual report. The company's revenue was 1,017 billion yuan,...
No Data